Septerna (NASDAQ:SEPN) Rating Increased to Strong-Buy at Wall Street Zen

Septerna (NASDAQ:SEPN) was upgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a note issued to investors on Saturday.

Other research analysts have also issued research reports about the company. Wells Fargo & Company upgraded Septerna from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $18.00 to $28.00 in a research report on Friday, November 14th. Raymond James Financial began coverage on shares of Septerna in a report on Friday. They set a “strong-buy” rating and a $38.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a report on Wednesday, October 8th. Truist Financial initiated coverage on shares of Septerna in a research report on Monday. They issued a “buy” rating and a $34.00 price objective on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $25.00 target price on shares of Septerna in a research report on Friday, September 5th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Septerna has an average rating of “Moderate Buy” and an average price target of $31.00.

Septerna Stock Up 7.4%

Shares of NASDAQ:SEPN opened at $29.58 on Friday. The company has a market cap of $1.32 billion, a PE ratio of -19.59 and a beta of 3.80. Septerna has a fifty-two week low of $4.17 and a fifty-two week high of $30.50. The firm has a 50-day simple moving average of $23.76 and a 200 day simple moving average of $16.87.

Septerna (NASDAQ:SEPN) last issued its earnings results on Monday, November 10th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.28). The company had revenue of $21.50 million during the quarter, compared to analyst estimates of $24.50 million. Septerna had a negative net margin of 266.77% and a negative return on equity of 17.98%. As a group, research analysts forecast that Septerna will post -7.11 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Daniel D. Long sold 3,501 shares of the stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $18.06, for a total value of $63,228.06. Following the completion of the transaction, the senior vice president owned 92,911 shares in the company, valued at $1,677,972.66. This represents a 3.63% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 4.30% of the stock is owned by insiders.

Institutional Trading of Septerna

A number of institutional investors have recently made changes to their positions in SEPN. Jacobs Levy Equity Management Inc. acquired a new position in shares of Septerna during the third quarter valued at approximately $673,000. PharVision Advisers LLC lifted its position in Septerna by 17.5% in the third quarter. PharVision Advisers LLC now owns 11,932 shares of the company’s stock worth $224,000 after purchasing an additional 1,780 shares during the period. VR Adviser LLC boosted its stake in Septerna by 13.0% during the 3rd quarter. VR Adviser LLC now owns 610,808 shares of the company’s stock valued at $11,489,000 after purchasing an additional 70,355 shares in the last quarter. Verition Fund Management LLC bought a new position in Septerna during the 3rd quarter valued at $379,000. Finally, Millennium Management LLC increased its position in shares of Septerna by 639.6% during the 3rd quarter. Millennium Management LLC now owns 384,200 shares of the company’s stock valued at $7,227,000 after purchasing an additional 332,256 shares during the period.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.